Observational studyBMC microbiology2026
Species distribution and antifungal susceptibility of Candida isolates from sterile body sites: a 14-year retrospective study at a tertiary care hospital in China (2010-2023).
Observational study in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInvasive candidiasis (IC) remains a major cause of morbidity and mortality worldwide, particularly among critically ill and immunocompromised patients. The emergence of antifungal resistance, especially to azoles, has complicated empirical and targeted therapy. Continuous, region-specific surveillance of Candida species distribution and antifungal susceptibility patterns is therefore essential.
methodsWe conducted a retrospective observational study of IC cases at Nanjing Drum Tower Hospital, a tertiary care center in eastern China, from January 2010 to December 2023. Candida isolates recovered from sterile body sites were identified to the species level. Antifungal susceptibility testing was performed using standardized commercial platforms, and results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Species distribution, temporal trends, ward-specific patterns, and antifungal susceptibility profiles were analyzed.
resultsA total of 1,038 non-duplicate Candida isolates were included. Candida albicans was the predominant species (51.1%), followed by C. parapsilosis (15.8%), C. tropicalis (15.5%), and C. glabrata (11.3%). Ascitic fluid (44.5%) and blood (38.2%) were the most common specimen sources, with most isolates originating from the intensive care unit and general surgery wards. Over the 14-year period, the proportions of C. albicans and C. glabrata increased significantly, whereas C. parapsilosis declined. Overall resistance rates to fluconazole and voriconazole were relatively low (3.0% and 2.9%, respectively). However, C. tropicalis exhibited higher azole resistance and non-wild-type phenotypes, particularly to posaconazole. Echinocandin and amphotericin B resistance was rare across major species.
conclusionsIn this tertiary-care hospital, C. albicans remained the most frequently isolated Candida species from sterile body sites, whereas C. tropicalis demonstrated the highest azole resistance burden. These findings highlight the importance of sustained local surveillance to inform empirical antifungal strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.